Syngene International (NSE:SYNG)

Executive Summary

Syngene International Ltd is a leading Indian contract research, development, and manufacturing organization (CRDMO) that provides end-to-end services across small molecules, biologics, and advanced modalities. Leveraging its proprietary SynVent integrated discovery platform and specialized centers like the Center for Advanced Protein Studies, the company supports pharmaceutical and biotechnology clients from target identification through GMP-grade commercial production. Founded in 2020 and publicly traded on the NSE under the ticker SYNG, Syngene has rapidly established itself as a trusted partner for global drug development, with a strong focus on oncology, immunology, and rare diseases. The company benefits from the growing trend of pharmaceutical outsourcing to India, driven by cost efficiencies and operational excellence. Syngene's comprehensive service offerings and state-of-the-art infrastructure position it well to capture increasing demand from both established pharma and emerging biotech firms, supporting robust revenue growth and margin expansion. With a large employee base of over 1,000 and a capital raise of $150 million, the company is well-capitalized to invest in capacity expansion and technological advancements, further solidifying its competitive edge in the global CRDMO market.

Upcoming Catalysts (preview)

• Q2 2026Major multi-year contract win with a top 10 global pharmaceutical company60% success
• Q4 2026Completion and operationalization of new biologics manufacturing facility in Bangalore70% success
• Q3 2026Strategic partnership for mRNA and cell therapy manufacturing services50% success